Exact Mass: 395.1321

A hydroxycoumarin that is the aglycone of novobiocin.

Benzomalvin C

(2S,3S)-6-Methyl-3-phenyl-13H-spiro[oxirane-2,7-quinazolino[3,2-a][1,4]benzodiazepine]-5,13(6H)-dione

Dehydrosaulatine

7-hydroxy-1-(1-hydroxyethyl)-8-methyl-2,3,8,9a,10,12a-hexahydro-6H-benzo[cd]furo[2,3:5,6]pyrano[3,4-g]pyrrolo[1,2-a]indole-6,11(1H)-dione

FDU-PB-22

C26H18FNO2 (395.1321)

Thalflavidine

3-Methyl-3-(6,7-dimethoxyisoquinoline-1-yl)-4,7-dimethoxyisobenzofuran-1(3H)-one

3-(6,7-Dimethoxy-isoquinolin-1-yl)-3-(3,4-dimethoxy-phenyl)-acrylic acid

"NCGC00160257-01!3-(6,7-Dimethoxy-isoquinolin-1-yl)-3-(3,4-dimethoxy-phenyl)-acrylic acid"

Benzomalvin C_120256

C24H17N3O3_Spiro[oxirane-2,7(13H)-quinazolino[3,2-a][1,4]benzodiazepine]-5,13(6H)-dione, 6-methyl-3-phenyl-, (2S,3S)

NCGC00180312-03_C24H17N3O3_Spiro[oxirane-2,7(13H)-quinazolino[3,2-a][1,4]benzodiazepine]-5,13(6H)-dione, 6-methyl-3-phenyl-, (2S,3S)-

(2S,3S)-6-methyl-3-phenylspiro[oxirane-2,7-quinazolino[3,2-a][1,4]benzodiazepine]-5,13-dione

Cys His His

C15H21N7O4S1 (395.1376)

His Cys His

C15H21N7O4S1 (395.1376)

Asp Phe Asp

His His Cys

C15H21N7O4S1 (395.1376)

N-(4,7-Dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)-2,2-dimethylchromane-6-carboxamide

[4-(2,4-difluorophenyl)-2-[(2,5-dimethylphenyl)carbamoyl]phenyl] acetate

C23H19F2NO3 (395.1333)

Fmoc-D-Asp(OAll)-OH

Grepafloxacin hydrochloride

C19H23ClFN3O3 (395.1412)

D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors

Fmoc-Asp-OAll

[4-(2,4-difluorophenyl)-2-(propylcarbamoyl)phenyl] benzoate

C23H19F2NO3 (395.1333)

Fmoc-Asp(OAll)-OH

Oxazine 4 perchlorate

C18H22ClN3O5 (395.1248)

N-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamide

C18H20F3N5S (395.1391)

methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate

C17H19F2N5O2S (395.1227)

5-(4-chlorophenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-furancarboxamide

C22H22ClN3O2 (395.14)

Asp-Asp-Phe

2-(3,4-Dimethoxyphenyl)-9-(4-fluorophenyl)-2,3-dihydropurine-6-carboxamide

C20H18FN5O3 (395.1394)

3-(3-Chloro-2-methylphenyl)-1-[(4-methylphenyl)methyl]-1-(3-pyridinylmethyl)thiourea

C22H22ClN3S (395.1223)

2-(2-methoxyethyl)-9-methyl-1-oxo-N-(thiophen-2-ylmethyl)-4-pyrido[3,4-b]indolecarboxamide

C21H21N3O3S (395.1304)

N-[3-(3-chlorophenyl)phenyl]-1-(3-isoxazolylmethyl)-4-piperidinecarboxamide

C22H22ClN3O2 (395.14)

Asp-Phe-Asp

His-His-Cys

C15H21N7O4S (395.1376)

Cys-His-His

C15H21N7O4S (395.1376)

His-Cys-His

C15H21N7O4S (395.1376)

Phe-Asp-Asp

Tetraethyl [(3-hydroxy-2-pyridyl)amino]methanediphosphonate

C15H27NO7P2 (395.1263)

(E)-3-(6,7-dimethoxyisoquinolin-1-yl)-3-(3,4-dimethoxyphenyl)prop-2-enoic acid

BE-54238B

An organic heterohexacyclic compound that is isolated from Streptomyces sp. A54238. It exhibits inhibitory efficacy against the growth of human tumour cells.

LPC 7:3;O2

C15H26NO9P (395.1345)

FASN-IN-1

C18H25N3O3S2 (395.1337)

FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56[1].

(2s,3r)-9'-methyl-3-phenyl-1',9',12'-triazaspiro[oxirane-2,10'-tetracyclo[9.8.0.0²,⁷.0¹³,¹⁸]nonadecane]-2',4',6',11',13',15',17'-heptaene-8',19'-dione

11-hydroxy-20-(1-hydroxyethyl)-9-methyl-4,8-dioxa-21-azahexacyclo[10.9.1.0²,¹⁰.0³,⁷.0¹⁶,²².0¹⁷,²¹]docosa-1,10,12(22),14,16-pentaene-5,13-dione

12-[2-(dimethylamino)ethyl]-13,14-dimethoxy-3,5,16-trioxapentacyclo[9.6.2.0²,⁶.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-1,6,8(18),9,11(19),12,14-heptaen-17-one

(2s,3s)-9'-methyl-3-phenyl-1',9',12'-triazaspiro[oxirane-2,10'-tetracyclo[9.8.0.0²,⁷.0¹³,¹⁸]nonadecane]-2',4',6',11',13',15',17'-heptaene-8',19'-dione

9'-methyl-3-phenyl-1',9',12'-triazaspiro[oxirane-2,10'-tetracyclo[9.8.0.0²,⁷.0¹³,¹⁸]nonadecane]-2',4',6',11',13',15',17'-heptaene-8',19'-dione